Thus, the absence of TRIM21/Ro52 results in aberrant NF-κB activation, which is also explicitly required for the proliferation of activated B-cell DLBCL, the main subtype of DLBCL found in SLE patients [30–32]. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.